Plasma Fractionation Market Size, Share, Trends, Growth Outlook

Plasma Fractionation Market is estimated to increase at a Compounded Annual Growth Rate of 6.4% CAGR over the forecast period from 2024 to 2030

The Plasma Fractionation Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, Others), By Application (Neurology, Immunology, Hematology, Pulmonology, Others), By End-User (Hospitals and Clinics, Clinical Research Laboratories, Academic institutes).

An Introduction to Plasma Fractionation Market in 2024

Plasma fractionation is a process of separating and purifying proteins from blood plasma to produce therapeutic plasma-derived products such as immunoglobulins, albumin, and coagulation factors. This market includes fractionation technologies, purification methods, and plasma-derived therapies used for treating various medical conditions, including immune disorders, bleeding disorders, and neurological diseases. Innovations in plasma fractionation focus on enhancing product purity, increasing production efficiency, ensuring viral safety, and meeting the growing demand for lifesaving plasma-derived therapies worldwide.

Market Trend: Increasing Demand for Plasma-Derived Therapies

A significant trend in the plasma fractionation market is the increasing demand for plasma-derived therapies. Plasma fractionation involves the separation of blood plasma into its component proteins, such as albumin, immunoglobulins, clotting factors, and alpha-1 antitrypsin, which are then used to produce therapeutic products for the treatment of various medical conditions. With advancements in biotechnology and healthcare, there has been a growing recognition of the therapeutic potential of plasma-derived proteins in managing autoimmune disorders, bleeding disorders, immune deficiencies, and other rare diseases. This trend reflects a rising demand for safe, effective, and biologically active plasma-derived therapies to address unmet medical needs and improve patient outcomes in clinical practice.

Market Driver: Increasing Incidence of Chronic Diseases and Immunodeficiencies

A key driver for the plasma fractionation market is the increasing incidence of chronic diseases and immunodeficiencies worldwide. Chronic diseases such as autoimmune disorders, hemophilia, and primary immunodeficiency diseases (PIDs) affect millions of people globally, leading to significant morbidity, mortality, and healthcare costs. Plasma-derived therapies, including immunoglobulins, clotting factors, and other plasma proteins, play a crucial role in managing these conditions by replacing deficient proteins, modulating immune responses, and preventing disease complications. As the prevalence of chronic diseases and immunodeficiencies continues to rise due to aging populations, lifestyle factors, and advances in disease diagnosis, there is a growing demand for plasma fractionation products that offer safe, effective, and reliable treatment options for patients across diverse therapeutic indications.

Market Opportunity: Expansion of Plasma Fractionation Capacity and Product Portfolio

An emerging opportunity within the plasma fractionation market lies in the expansion of plasma fractionation capacity and product portfolio. With increasing demand for plasma-derived therapies and advancements in bioprocessing technologies, there is a need for plasma fractionation facilities to scale up production capacity, optimize manufacturing processes, and diversify product offerings to meet market demand. By investing in infrastructure expansion, process optimization, and product development initiatives, manufacturers can enhance their plasma fractionation capabilities, increase production efficiency, and introduce new therapeutic products to address emerging therapeutic areas and patient needs. This presents an opportunity to expand market presence, capture new revenue streams, and contribute to improving patient access to life-saving plasma-derived therapies on a global scale.

Plasma Fractionation Market Share Analysis: Immunoglobulins Segment is the fastest growing segment over the forecast period to 2030

The immunoglobulins segment is experiencing the fastest growth within the plasma fractionation market. This growth is primarily driven by several factors. Firstly, there is a growing prevalence of autoimmune and immunodeficiency disorders globally, which has led to an increased demand for immunoglobulin therapies for the management of these conditions. Intravenous immunoglobulins (IVIG) and subcutaneous immunoglobulins (SCIG) are particularly witnessing significant uptake due to their efficacy in treating various autoimmune diseases, neurological disorders, and primary immunodeficiencies. Moreover, advancements in plasma fractionation techniques have improved the purity and safety profiles of immunoglobulin products, boosting their adoption among healthcare providers and patients. Additionally, the expanding applications of immunoglobulin therapies across different medical specialties, including neurology, immunology, hematology, and pulmonology, further contribute to the growth of this segment. Hospitals and clinics are the primary end-users of immunoglobulin products, followed by clinical research laboratories and academic institutes, reflecting the broad utilization of these therapies in both clinical practice and research settings. Consequently, the immunoglobulins segment emerges as the fastest-growing segment within the plasma fractionation market.

Plasma Fractionation Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossADMA Biologics Inc, Bharat Serums and Vaccines Ltd, Centurion Pharma, China Biologic Products Holdings Inc, CSL Ltd, Emergent BioSolutions Inc, Fusion Healthcare, GC Pharma, Grifols S.A., Hemarus Therapeutics Ltd, Hualan Biological Engineering Inc, Intas Pharmaceuticals Ltd, Japan Blood Products Organization, Kamada Ltd, Kedrion S.p.A., LFB SA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd, Prothya Biosolutions Pvt. Ltd, Sanquin Blood Supply Foundation, Shanghai RAAS Blood Products Co. Ltd, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd, SK Plasma Co. Ltd, Takeda Pharmaceutical Company Ltd, Virchow Biotech Private Ltd

Plasma Fractionation Market Segmentation

By Product
Immunoglobulins
-Intravenous Immunoglobulins
-Subcutaneous Immunoglobulins
-Others
Coagulation Factor Concentrates
-Factor VIII
-Factor IX
-Von Willebrand Factor
-Others
Albumin
Protease Inhibitors
Others
By Application
Neurology
Immunology
Hematology
Pulmonology
Others
By End-User
Hospitals and Clinics
Clinical Research Laboratories
Academic institutes
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Plasma Fractionation Market Companies

ADMA Biologics Inc
Bharat Serums and Vaccines Ltd
Centurion Pharma
China Biologic Products Holdings Inc
CSL Ltd
Emergent BioSolutions Inc
Fusion Healthcare
GC Pharma
Grifols S.A.
Hemarus Therapeutics Ltd
Hualan Biological Engineering Inc
Intas Pharmaceuticals Ltd
Japan Blood Products Organization
Kamada Ltd
Kedrion S.p.A.
LFB SA
Octapharma AG
PlasmaGen BioSciences Pvt. Ltd
Prothya Biosolutions Pvt. Ltd
Sanquin Blood Supply Foundation
Shanghai RAAS Blood Products Co. Ltd
Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd
SK Plasma Co. Ltd
Takeda Pharmaceutical Company Ltd
Virchow Biotech Private Ltd

Reasons to Buy the Plasma Fractionation Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Plasma Fractionation Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Plasma Fractionation Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Plasma Fractionation Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Plasma Fractionation Market Size Outlook, $ Million, 2021 to 2030
3.2 Plasma Fractionation Market Outlook by Type, $ Million, 2021 to 2030
3.3 Plasma Fractionation Market Outlook by Product, $ Million, 2021 to 2030
3.4 Plasma Fractionation Market Outlook by Application, $ Million, 2021 to 2030
3.5 Plasma Fractionation Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Plasma Fractionation Industry
4.2 Key Market Trends in Plasma Fractionation Industry
4.3 Potential Opportunities in Plasma Fractionation Industry
4.4 Key Challenges in Plasma Fractionation Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Plasma Fractionation Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Plasma Fractionation Market Outlook by Segments
7.1 Plasma Fractionation Market Outlook by Segments, $ Million, 2021- 2030
By Product
Immunoglobulins
-Intravenous Immunoglobulins
-Subcutaneous Immunoglobulins
-Others
Coagulation Factor Concentrates
-Factor VIII
-Factor IX
-Von Willebrand Factor
-Others
Albumin
Protease Inhibitors
Others
By Application
Neurology
Immunology
Hematology
Pulmonology
Others
By End-User
Hospitals and Clinics
Clinical Research Laboratories
Academic institutes

8 North America Plasma Fractionation Market Analysis and Outlook To 2030
8.1 Introduction to North America Plasma Fractionation Markets in 2024
8.2 North America Plasma Fractionation Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Plasma Fractionation Market size Outlook by Segments, 2021-2030
By Product
Immunoglobulins
-Intravenous Immunoglobulins
-Subcutaneous Immunoglobulins
-Others
Coagulation Factor Concentrates
-Factor VIII
-Factor IX
-Von Willebrand Factor
-Others
Albumin
Protease Inhibitors
Others
By Application
Neurology
Immunology
Hematology
Pulmonology
Others
By End-User
Hospitals and Clinics
Clinical Research Laboratories
Academic institutes

9 Europe Plasma Fractionation Market Analysis and Outlook To 2030
9.1 Introduction to Europe Plasma Fractionation Markets in 2024
9.2 Europe Plasma Fractionation Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Plasma Fractionation Market Size Outlook by Segments, 2021-2030
By Product
Immunoglobulins
-Intravenous Immunoglobulins
-Subcutaneous Immunoglobulins
-Others
Coagulation Factor Concentrates
-Factor VIII
-Factor IX
-Von Willebrand Factor
-Others
Albumin
Protease Inhibitors
Others
By Application
Neurology
Immunology
Hematology
Pulmonology
Others
By End-User
Hospitals and Clinics
Clinical Research Laboratories
Academic institutes

10 Asia Pacific Plasma Fractionation Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Plasma Fractionation Markets in 2024
10.2 Asia Pacific Plasma Fractionation Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Plasma Fractionation Market size Outlook by Segments, 2021-2030
By Product
Immunoglobulins
-Intravenous Immunoglobulins
-Subcutaneous Immunoglobulins
-Others
Coagulation Factor Concentrates
-Factor VIII
-Factor IX
-Von Willebrand Factor
-Others
Albumin
Protease Inhibitors
Others
By Application
Neurology
Immunology
Hematology
Pulmonology
Others
By End-User
Hospitals and Clinics
Clinical Research Laboratories
Academic institutes

11 South America Plasma Fractionation Market Analysis and Outlook To 2030
11.1 Introduction to South America Plasma Fractionation Markets in 2024
11.2 South America Plasma Fractionation Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Plasma Fractionation Market size Outlook by Segments, 2021-2030
By Product
Immunoglobulins
-Intravenous Immunoglobulins
-Subcutaneous Immunoglobulins
-Others
Coagulation Factor Concentrates
-Factor VIII
-Factor IX
-Von Willebrand Factor
-Others
Albumin
Protease Inhibitors
Others
By Application
Neurology
Immunology
Hematology
Pulmonology
Others
By End-User
Hospitals and Clinics
Clinical Research Laboratories
Academic institutes
12 Middle East and Africa Plasma Fractionation Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Plasma Fractionation Markets in 2024
12.2 Middle East and Africa Plasma Fractionation Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Plasma Fractionation Market size Outlook by Segments, 2021-2030
By Product
Immunoglobulins
-Intravenous Immunoglobulins
-Subcutaneous Immunoglobulins
-Others
Coagulation Factor Concentrates
-Factor VIII
-Factor IX
-Von Willebrand Factor
-Others
Albumin
Protease Inhibitors
Others
By Application
Neurology
Immunology
Hematology
Pulmonology
Others
By End-User
Hospitals and Clinics
Clinical Research Laboratories
Academic institutes

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
ADMA Biologics Inc
Bharat Serums and Vaccines Ltd
Centurion Pharma
China Biologic Products Holdings Inc
CSL Ltd
Emergent BioSolutions Inc
Fusion Healthcare
GC Pharma
Grifols S.A.
Hemarus Therapeutics Ltd
Hualan Biological Engineering Inc
Intas Pharmaceuticals Ltd
Japan Blood Products Organization
Kamada Ltd
Kedrion S.p.A.
LFB SA
Octapharma AG
PlasmaGen BioSciences Pvt. Ltd
Prothya Biosolutions Pvt. Ltd
Sanquin Blood Supply Foundation
Shanghai RAAS Blood Products Co. Ltd
Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd
SK Plasma Co. Ltd
Takeda Pharmaceutical Company Ltd
Virchow Biotech Private Ltd

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Immunoglobulins
-Intravenous Immunoglobulins
-Subcutaneous Immunoglobulins
-Others
Coagulation Factor Concentrates
-Factor VIII
-Factor IX
-Von Willebrand Factor
-Others
Albumin
Protease Inhibitors
Others
By Application
Neurology
Immunology
Hematology
Pulmonology
Others
By End-User
Hospitals and Clinics
Clinical Research Laboratories
Academic institutes
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)